Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
ABBV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$153.58 - $218.66
Previous CloseN/A
Volume1.02M
Average Volume (3M)6.99M
Market Cap
$364.89B
Enterprise Value$376.68B
Total Cash (Recent Filing)$41.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)86.3
Beta0.15
Next Earnings
Apr 25, 2025EPS Estimate
2.51Next Dividend Ex-Date
Apr 15, 2025Dividend Yield3.05%
Share Statistics
EPS (TTM)2.39
Shares Outstanding1,768,978,300
10 Day Avg. Volume8,255,349
30 Day Avg. Volume6,988,273
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.58
Price to Cash Flow (P/CF)13.20
P/FCF Ratio12.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.55
Enterprise Value/Ebitda20.75
Forecast
1Y Price Target
$215.57Price Target Upside5.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceHigher immunology sales have driven an increase in EPS forecasts and a higher DrugBank NPV.
Strategic CollaborationsThe agreement with Gubra to develop an Amylin Analog for obesity treatment represents a strategic collaboration for Abbvie.
Strategic ExpansionAbbvie's recent in-licensing of rights to GUBamy marks the company's entry into the obesity space.
Bears Say
Impairment CostsThe disappointing schizophrenia readout for emraclidine led to a USD4.5bn impairment for Cerevel.
Treatment TolerabilityGI-related adverse events were dose dependent, with the highest dose having an 83% nausea and 17% vomiting rate, indicating potential challenges in treatment tolerability.
Valuation ConcernsAbbVie trades on a P/E of 15.6x, above the US sector median, indicating a full valuation.
---
Ownership Overview
0.08% Insiders
21.64% Mutual Funds
14.77% Other Institutional Investors
41.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $153.58 and its highest was $218.66 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $364.89B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Apr 25, 2025 which is in 21 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jan 31, 2025. The company reported $2.16 earnings per share for the quarter, beating the consensus estimate of $2.115 by $0.045.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.639 which represents an annual dividend yield of 3.05%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 2.51.
How many shares outstanding does AbbVie have?
AbbVie has 1,768,978,300 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.16 in its last earnings report, beating expectations of $2.115. Following the earnings report the stock price went up 4.697%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
---
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$215.57 (5.06% Upside)
$215.57 (5.06% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 93%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $69.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.69%
12-Months-Change
Fundamentals
Return on Equity
61.94%
Trailing 12-Months
Asset Growth
0.33%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. is a global, research-driven biopharmaceutical company that focuses on developing and delivering innovative medicines and therapies. Established in 2013 as a spin-off from Abbott Laboratories, AbbVie operates in the healthcare sector, primarily focusing on immunology, oncology, virology, and neuroscience. The company is known for its robust portfolio of products, including its flagship drug Humira, along with other significant treatments like Imbruvica and Venclexta.
---
ABBV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong financial performance in 2024 with notable growth in its ex-Humira platform and advancements in neuroscience and oncology. However, challenges persist with Humira revenue erosion and the aesthetic market facing economic headwinds. Overall, the company is poised for robust growth in 2025 despite these challenges.Read More>---
ABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
---
ABBV Stock 12 Month Forecast
Average Price Target
$215.57
▲(5.06% Upside)
Technical Analysis
Best Analysts Covering ABBV
1 Year
1 Year Success Rate
39/41 ratings generated profit
1 Year Average Return
+24.12%
assigned a buy rating 2 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 95.12% of your transactions generating a profit, with an average return of +24.12% per trade.
---